PORTALJABAR, BANDUNG CITY - IndoVac, which is a COVID-19 vaccine based on recombinant protein subunit technology which is used as an active immunization against COVID-19 produced by Bio Farma, has obtained approval for a Marketing Permit from the Food and Drug Supervisory Agency (BPOM) through a letter released by BPOM on December 09, 2023.

The Main Director of Bio Farma, Shadiq Akasya, said that the IndoVac vaccine has received an Emergency Use Authorization (EUA) from BPOM.

"Previously, the IndoVac vaccine had received an Emergency Use Authorization (EUA) from BPOM in January 2021, therefore with the issuance of the NIE from BPOM, the EUA for the IndoVac vaccine is no longer valid," said Shadiq, Tuesday (2/1/2023 ).

“The IndoVac vaccine can be given to patients starting from the age of 18 years. "Currently, IndoVac has also obtained a halal and MUI fatwa and a halal certificate from BPJPH, the Ministry of Religion and is a domestic product created by the nation's children with a domestic content level (TKDN) reaching 89.84%," he added.

IndoVac is a COVID-19 vaccine based on recombinant protein subunit technology which is used as active immunization against COVID-19 caused by the SARS-CoV-2 virus. This vaccine has a 5 ml vial dosage form, containing 10 doses of vaccine per vial which is a vaccine made from inactivated viruses.

Packaged in a box containing 10 vials, stable for storage at a temperature of 2°-8°C. Each vial is equipped with a 2D Barcode which shows the identity of each vial, and functions to track and prevent fake vaccines.

Vaccination has been proven to be an effective prevention strategy in controlling the COVID-19 pandemic from becoming endemic. To anticipate the domestic need for the IndoVac vaccine, Bio Farma will continue to coordinate with related parties regarding the provision of an IndoVac vaccine that is efficient and meets standards. (no/rdp*)